関連レポート

出版元：Transparency Market Research  出版元について

発行年：2024年7月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 153ページになります。

商品コード：TMR317

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

ｍRNAワクチンおよび治療薬の世界市場規模は2023年で196億ドル、2034年に859億ドル、市場の平均年成長率は14.6%にて増加する見込みです。

当レポートでは、ｍRNAワクチンおよび治療薬の市場予測-2034年、各種セグメント別市場分析(ｍRNAタイプ別、タイプ別、国地域別、等)、パイプライン分析、主要製品/ブランド分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】
■ｍRNAワクチンおよび治療薬の世界市場予測2020-2034年
・市場規模(US$)

■mRNAタイプ別、市場-2034年
・ヌクレオシド修飾mRNA
・非修飾mRNA
・自己増幅型mRNA
※(市場規模US$)　

■タイプ別、市場-2034年
・予防
・治療
※(市場規模US$)　

■用途別、市場-2034年
・感染症
・腫瘍学
・希少遺伝子疾患
・その他（呼吸器疾患など）
※(市場規模US$)

■エンドユーザー別、市場-2034年
・病院、クリニック
・バイオ製薬会社
・その他（研究機関など）
※(市場規模US$)　

■主要国地域別市場-2034年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
市場ダイナミクス
パイプライン分析
主要製品/ブランド分析
主要な合併、買収

■ｍRNAワクチンおよび治療薬の主要企業プロフィール動向
Moderna, Inc.
BioNTech SE.
CureVac SE
Arcturus Therapeutics, Inc.
Sanofi
GSK plc
Argos Therapeutics Inc.
Ethris
Pfizer Inc.
AstraZeneca
（全153頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global mRNA Vaccines and Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, 2020-2034

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by mRNA Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by mRNA Type, 2020-2034
6.3.1. Nucleoside-modified mRNA
6.3.2. Unmodified mRNA
6.3.3. Self-amplifying mRNA
6.4. Market Attractiveness, by mRNA Type

7. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by Type
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Type, 2020-2034
7.3.1. Prophylactic
7.3.2. Therapeutic
7.3.3. 7.4 Market Attractiveness, by Type

8. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by Application
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2020-2034
8.3.1. Infectious Diseases
8.3.2. Oncology
8.3.3. Rare Genetic Diseases
8.3.4. Others (Respiratory Diseases, etc.)
8.4. Market Attractiveness, by Application

9. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospitals & Clinics
9.3.2. Biopharmaceutical Companies
9.3.3. Others (Research Organizations, etc.)
9.4. Market Attractiveness, by End-user

10. Global mRNA Vaccines and Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region

11. North America mRNA Vaccines and Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by mRNA Type, 2020-2034
11.2.1. Nucleoside-modified mRNA
11.2.2. Unmodified mRNA
11.2.3. Self-amplifying mRNA
11.3. Market Attractiveness, by mRNA Type
11.4. Market Value Forecast, by Type, 2020-2034
11.4.1. Prophylactic
11.4.2. Therapeutic
11.5. Market Attractiveness, by Type
11.6. Market Value Forecast, by Application, 2020-2034
11.6.1. Infectious Diseases
11.6.2. Oncology
11.6.3. Rare Genetic Diseases
11.6.4. Others (Respiratory Diseases, etc.)
11.7. Market Attractiveness, by Application
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospitals & Clinics
11.8.2. Biopharmaceutical Companies
11.8.3. Others (Research Organizations, etc.)
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By mRNA Type
11.11.2. By Type
11.11.3. By Application
11.11.4. By End-user
11.11.5. By Country

12. Europe mRNA Vaccines and Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by mRNA Type, 2020-2034
12.2.1. Nucleoside-modified mRNA
12.2.2. Unmodified mRNA
12.2.3. Self-amplifying mRNA
12.3. Market Attractiveness, by mRNA Type
12.4. Market Value Forecast, by Type, 2020-2034
12.4.1. Prophylactic
12.4.2. Therapeutic
12.5. Market Attractiveness, by Type
12.6. Market Value Forecast, by Application, 2020-2034
12.6.1. Infectious Diseases
12.6.2. Oncology
12.6.3. Rare Genetic Diseases
12.6.4. Others (Respiratory Diseases, etc.)
12.7. Market Attractiveness, by Application
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospitals & Clinics
12.8.2. Biopharmaceutical Companies
12.8.3. Others (Research Organizations, etc.)
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By mRNA Type
12.11.2. By Type
12.11.3. By Application
12.11.4. By End-user
12.11.5. By Country/Sub-region

13. Asia Pacific mRNA Vaccines and Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by mRNA Type, 2020-2034
13.2.1. Nucleoside-modified mRNA
13.2.2. Unmodified mRNA
13.2.3. Self-amplifying mRNA
13.3. Market Attractiveness, by mRNA Type
13.4. Market Value Forecast, by Type, 2020-2034
13.4.1. Prophylactic
13.4.2. Therapeutic
13.5. Market Attractiveness, by Type
13.6. Market Value Forecast, by Application, 2020-2034
13.6.1. Infectious Diseases
13.6.2. Oncology
13.6.3. Rare Genetic Diseases
13.6.4. Others (Respiratory Diseases, etc.)
13.7. Market Attractiveness, by Application
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Hospitals & Clinics
13.8.2. Biopharmaceutical Companies
13.8.3. Others (Research Organizations, etc.)
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By mRNA Type
13.11.2. By Type
13.11.3. By Application
13.11.4. By End-user
13.11.5. By Country/Sub-region

14. Latin America mRNA Vaccines and Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by mRNA Type, 2020-2034
14.2.1. Nucleoside-modified mRNA
14.2.2. Unmodified mRNA
14.2.3. Self-amplifying mRNA
14.3. Market Attractiveness, by mRNA Type
14.4. Market Value Forecast, by Type, 2020-2034
14.4.1. Prophylactic
14.4.2. Therapeutic
14.5. Market Attractiveness, by Type
14.6. Market Value Forecast, by Application, 2020-2034
14.6.1. Infectious Diseases
14.6.2. Oncology
14.6.3. Rare Genetic Diseases
14.6.4. Others (Respiratory Diseases, etc.)
14.7. Market Attractiveness, by Application
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospitals & Clinics
14.8.2. Biopharmaceutical Companies
14.8.3. Others (Research Organizations, etc.)
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By mRNA Type
14.11.2. By Type
14.11.3. By Application
14.11.4. By End-user
14.11.5. By Country/Sub-region

15. Middle East & Africa mRNA Vaccines and Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by mRNA Type, 2020-2034
15.2.1. Nucleoside-modified mRNA
15.2.2. Unmodified mRNA
15.2.3. Self-amplifying mRNA
15.3. Market Attractiveness, by mRNA Type
15.4. Market Value Forecast, by Type, 2020-2034
15.4.1. Prophylactic
15.4.2. Therapeutic
15.5. Market Attractiveness, by Type
15.6. Market Value Forecast, by Application, 2020-2034
15.6.1. Infectious Diseases
15.6.2. Oncology
15.6.3. Rare Genetic Diseases
15.6.4. Others (Respiratory Diseases, etc.)
15.7. Market Attractiveness, by Application
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospitals & Clinics
15.8.2. Biopharmaceutical Companies
15.8.3. Others (Research Organizations, etc.)
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By mRNA Type
15.11.2. By Type
15.11.3. By Application
15.11.4. By End-user
15.11.5. By Country/Sub-region

16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Moderna, Inc
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. BioNTech SE.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. CureVac SE
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Arcturus Therapeutics, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Sanofi
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. GSK plc
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Argos Therapeutics Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Ethris
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Pfizer Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. AstraZeneca
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview

List of Tables

Table 01: Global mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by mRNA Type, 2020-2034

Table 02: Global mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Type, 2020-2034

Table 03: Global mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 04: Global mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Application, 2020-2034

Table 05: Global mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Region, 2020-2034

Table 06: North America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Country, 2020-2034

Table 07: North America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by mRNA Type, 2020-2034

Table 08: North America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Type, 2020-2034

Table 09: North America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Application, 2020-2034

Table 10: North America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 11: Europe mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 12: Europe mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by mRNA Type, 2020-2034

Table 13: Europe mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Type, 2020-2034

Table 14: Europe mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Application, 2020-2034

Table 15: Europe mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 16: Asia Pacific mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 17: Asia Pacific mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by mRNA Type, 2020-2034

Table 18: Asia Pacific mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Type, 2020-2034

Table 19: Asia Pacific mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Application, 2020-2034

Table 20: Asia Pacific mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 21: Latin America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 22: Latin America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by mRNA Type, 2020-2034

Table 23: Latin America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Type, 2020-2034

Table 24: Latin America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Application, 2020-2034

Table 25: Latin America mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034

Table 26: Middle East & Africa mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

Table 27: Middle East & Africa mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by mRNA Type, 2020-2034

Table 28: Middle East & Africa mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Type, 2020-2034

Table 29: Middle East & Africa mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by Application, 2020-2034

Table 30: Middle East & Africa mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

Figure 01: Global mRNA Vaccines and Therapeutics Market Size (US$ Bn), by Region, 2023 and 2034

Figure 02: Global mRNA Vaccines and Therapeutics Market Revenue (US$ Bn), by mRNA Type, 2023

Figure 03: Global mRNA Vaccines and Therapeutics Market Value Share, by mRNA Type, 2023

Figure 04: Global mRNA Vaccines and Therapeutics Market Revenue (US$ Bn), by Type, 2023

Figure 05: Global mRNA Vaccines and Therapeutics Market Value Share, by Type, 2023

Figure 06: Global mRNA Vaccines and Therapeutics Market Revenue (US$ Bn), by Application, 2023

Figure 07: Global mRNA Vaccines and Therapeutics Market Value Share, by Application, 2023

Figure 08: Global mRNA Vaccines and Therapeutics Market Revenue (US$ Bn), by End-user, 2023

Figure 09: Global mRNA Vaccines and Therapeutics Market Value Share, by End-user, 2023

Figure 10: Global mRNA Vaccines and Therapeutics Market Value Share, by Region, 2023

Figure 11: Global mRNA Vaccines and Therapeutics Market Value (US$ Bn) Forecast, 2020-2034

Figure 12: Global mRNA Vaccines and Therapeutics Market Value Share Analysis, by mRNA Type, 2023 and 2034

Figure 13: Global mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by mRNA Type, 2024-2034

Figure 14: Global mRNA Vaccines and Therapeutics Market Value Share Analysis, by Type, 2023 and 2034

Figure 15: Global mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Type, 2024-2034

Figure 16: Global mRNA Vaccines and Therapeutics Market Value Share Analysis, by Application, 2023 and 2034

Figure 17: Global mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Application, 2024-2034

Figure 18: Global mRNA Vaccines and Therapeutics Market Revenue (US$ Bn), by End-user, 2023

Figure 19: Global mRNA Vaccines and Therapeutics Market Value Share, by End-user, 2023

Figure 20: Global mRNA Vaccines and Therapeutics Market Value Share Analysis, by Region, 2023 and 2034

Figure 21: Global mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Region, 2024-2034

Figure 22: North America mRNA Vaccines and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 23: North America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Country, 2024-2034

Figure 24: North America mRNA Vaccines and Therapeutics Market Value Share Analysis, by Country, 2023 and 2034

Figure 25: North America mRNA Vaccines and Therapeutics Market Value Share Analysis, by mRNA Type, 2023 and 2034

Figure 26: North America mRNA Vaccines and Therapeutics Market Value Share Analysis, by Type, 2023 and 2034

Figure 27: North America mRNA Vaccines and Therapeutics Market Value Share Analysis, by Application, 2023 and 2034

Figure 28: North America mRNA Vaccines and Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034

Figure 29: North America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by mRNA Type, 2024-2034

Figure 30: North America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Type, 2024-2034

Figure 31: North America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Application, 2024-2034

Figure 32: North America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034

Figure 33: Europe mRNA Vaccines and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 34: Europe mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 35: Europe mRNA Vaccines and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 36: Europe mRNA Vaccines and Therapeutics Market Value Share Analysis, by mRNA Type, 2023 and 2034

Figure 37: Europe mRNA Vaccines and Therapeutics Market Value Share Analysis, by Type, 2023 and 2034

Figure 38: Europe mRNA Vaccines and Therapeutics Market Value Share Analysis, by Application, 2023 and 2034

Figure 39: Europe mRNA Vaccines and Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034

Figure 40: Europe mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by mRNA Type, 2024-2034

Figure 41: Europe mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Type, 2024-2034

Figure 42: Europe mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Application, 2024-2034

Figure 43: Europe mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034

Figure 44: Asia Pacific mRNA Vaccines and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 45: Asia Pacific mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 46: Asia Pacific mRNA Vaccines and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 47: Asia Pacific mRNA Vaccines and Therapeutics Market Value Share Analysis, by mRNA Type, 2023 and 2034

Figure 48: Asia Pacific mRNA Vaccines and Therapeutics Market Value Share Analysis, by Type, 2023 and 2034

Figure 49: Asia Pacific mRNA Vaccines and Therapeutics Market Value Share Analysis, by Application, 2023 and 2034

Figure 50: Asia Pacific mRNA Vaccines and Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034

Figure 51: Asia Pacific mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by mRNA Type, 2024-2034

Figure 52: Asia Pacific mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Type, 2024-2034

Figure 53: Asia Pacific mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Application, 2024-2034

Figure 54: Asia Pacific mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034

Figure 55: Latin America mRNA Vaccines and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 56: Latin America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 57: Latin America mRNA Vaccines and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 58: Latin America mRNA Vaccines and Therapeutics Market Value Share Analysis, by mRNA Type, 2023 and 2034

Figure 59: Latin America mRNA Vaccines and Therapeutics Market Value Share Analysis, by Type, 2023 and 2034

Figure 60: Latin America mRNA Vaccines and Therapeutics Market Value Share Analysis, by Application, 2023 and 2034

Figure 61: Latin America mRNA Vaccines and Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034

Figure 62: Latin America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by mRNA Type, 2024-2034

Figure 63: Latin America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Type, 2024-2034

Figure 64: Latin America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Application, 2024-2034

Figure 65: Latin America mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034

Figure 66: Middle East & Africa mRNA Vaccines and Therapeutics Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 67: Middle East & Africa mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 68: Middle East & Africa mRNA Vaccines and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 69: Middle East & Africa mRNA Vaccines and Therapeutics Market Value Share Analysis, by mRNA Type, 2023 and 2034

Figure 70: Middle East & Africa mRNA Vaccines and Therapeutics Market Value Share Analysis, by Type, 2023 and 2034

Figure 71: Middle East & Africa mRNA Vaccines and Therapeutics Market Value Share Analysis, by Application, 2023 and 2034

Figure 72: Middle East & Africa mRNA Vaccines and Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034

Figure 73: Middle East & Africa mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by mRNA Type, 2024-2034

Figure 74: Middle East & Africa mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Type, 2024-2034

Figure 75: Middle East & Africa mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by Application, 2024-2034

Figure 76: Middle East & Africa mRNA Vaccines and Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034

△ 一番上に戻る